Insider Selling: Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,730 shares of Alpha Tau Medical stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total value of $248,220.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at $1,262,520. The trade was a 16.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total value of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total value of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Trading Down 1.7%

NASDAQ DRTS opened at $14.25 on Friday. The firm has a 50 day simple moving average of $11.93 and a 200-day simple moving average of $9.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.79 and a current ratio of 11.09. Alpha Tau Medical Ltd. has a one year low of $3.00 and a one year high of $14.75. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -13.70 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.36). The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.14 million. Equities research analysts anticipate that Alpha Tau Medical Ltd. will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. HC Wainwright upped their price objective on Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday. LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Barclays boosted their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Finally, Piper Sandler increased their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.80.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently modified their holdings of DRTS. Trifecta Capital Advisors LLC purchased a new position in Alpha Tau Medical in the fourth quarter valued at $48,000. Envestnet Asset Management Inc. acquired a new stake in Alpha Tau Medical in the third quarter valued at $62,000. Bank of America Corp DE lifted its holdings in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after buying an additional 17,500 shares during the last quarter. Finally, Everhart Financial Group Inc. purchased a new stake in Alpha Tau Medical during the 2nd quarter worth about $126,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Key Alpha Tau Medical News

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright raised its price target for Alpha Tau Medical to $16 from $15 and reiterated a “Buy” rating. The target remains above the recently referenced share price, indicating potential upside and providing some support for DRTS. HC Wainwright forecast for Alpha Tau Medical
• Positive Sentiment: DRTS recently reached a new 12-month high, reflecting strong investor momentum and optimism surrounding Alpha Tau Medical’s targeted alpha-radiation cancer therapy platform. Alpha Tau Medical reaches a new 12-month high
• Neutral Sentiment: Analyst coverage remains broadly favorable: five analysts rate the stock Buy, two rate it Hold and one rates it Sell, producing a consensus “Moderate Buy” rating. However, the average target price of $12.80 is below recent trading levels, suggesting valuation-related risk.
• Negative Sentiment: Chief Financial Officer Raphi Levy sold 17,730 shares at an average price of $14, generating proceeds of approximately $248,220 and reducing his ownership by 16.43%. Although the transaction was executed under a pre-arranged Rule 10b5-1 plan, the sale can pressure the stock by signaling insider profit-taking. Raphi Levy sells Alpha Tau Medical shares
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $1.05 from a loss of $0.67 and trimmed its FY2027 estimate to a loss of $0.60 from a loss of $0.55. Quarterly 2026 and 2027 loss estimates were also lowered to $0.15 per share from $0.14, indicating expectations for prolonged losses despite the Buy rating and $16 target.
• Negative Sentiment: Alpha Tau Medical’s latest quarterly results missed expectations, with an EPS loss of $0.50 versus the projected $0.14 loss and revenue of $0.10 million versus the expected $0.14 million. The sizable earnings miss reinforces concerns about operating performance and near-term cash burn.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.